Fagron SA ( (GB:0HNZ) ) just unveiled an update.
Fagron reported a strong financial performance for 2024, achieving a 14.3% increase in revenue and a 16.8% rise in REBITDA, driven by growth across all regions and segments. The company announced several acquisitions to strengthen its industry positioning and expects continued organic revenue growth and profitability improvements in 2025, highlighting its ability to execute strategic deals while maintaining financial discipline.
More about Fagron SA
Fagron is a leading global player in the pharmaceutical compounding industry, focusing on providing tailored pharmaceutical solutions. The company operates across various regions, including EMEA, Latin America, and North America, with a commitment to maintaining high-quality standards and expanding its market presence through strategic acquisitions.
YTD Price Performance: 20.16%
Average Trading Volume: 6,788
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1.46B
See more insights into 0HNZ stock on TipRanks’ Stock Analysis page.